Forbion is a global life sciences venture capital firm dedicated to advancing breakthrough biotech innovations and sustainable solutions that improve the health of people and the planet. We manage €5bn across multiple fund strategies that cover all stages of pharmaceutical and biotech drug development. Our platform includes Forbion Ventures, Growth and BioEconomy funds, plus joint ventures with BioGeneration Ventures for early stage activity. With offices in Naarden, The Netherlands; Munich, Germany; and Boston, USA, Forbion combines scientific expertise with investment discipline to source, build and guide companies from research to markets. Our team includes over 50 professionals across three offices, and we pursue investments across Europe and North America, aiming to generate meaningful patient impact and financial returns.
Since our origins in 2000 as ABN AMRO Capital Life Sciences and the 2006 spin out to form Forbion Capital Partners, we have evolved into a leading European life sciences venture capital firm. We apply rigorous due diligence, hands on portfolio support and a commitment to responsible investment to back teams tackling difficult diseases and planetary health challenges. By combining deep drug development know how with capital and strategic guidance, we accelerate the journey from discovery to therapy and scalable technology, delivering value to patients, entrepreneurs and investors alike.
